Psoriasis - an inflammatory skin disease with a genetic basis
Conditions
Interventions
Trade Name: Dovonex ointment
Product Name: Dovonex ointment
Pharmaceutical Form: Ointment
Sponsors
University Hospitals of Leicester NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 to 80 years who have psoriasis 2. Patients who are not currently having oral therapy or phototherapy for their psoriasis and have not received these therapies within the previous 3 months 3. Females of child-bearing potential who provide a negative urine pregnancy test and who agree not to become pregnant during the duration of the study Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Pregnant or breast-feeding females 2. Patients who have previously experienced local skin irritation from calcipotriol (Dovonex) 3. Patients who have received oral or photo-therapy for psoriasis during the preceding 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To investigate the effect of naturally occurring genetic variations (polymorphisms) in the Vitamin D receptor (VDR) gene on the response of psoriasis to treatment with a Vitamin D analogue product (Dovonex). ;Secondary Objective: To determine whether the underlying mechanism of response is determined by immunological molecular mechanisms.; Primary end point(s): The primary end point is the assessment of response of the plaques of psoriasis to the application of Dovonex ointment twice daily for 4 weeks. Response will be assessed in terms of erythema, induration and scaling of each plaque. This data will then be used to determine if there is a realationship between response to topical Dovonex and Vitamin D Receptor genotypes. | — |
Countries
United Kingdom
Outcome results
None listed